adenosine diphosphate has been researched along with cardiovascular agents in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (46.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Michel, G; Seipp, U | 1 |
| Bull, H; Machin, SJ; Mackie, IJ; Yardumian, DA | 1 |
| Colli, S; Maderna, P; Paoletti, R; Sirtori, C; Tremoli, E | 1 |
| Fitscha, P; Sinzinger, H; Tiso, B | 1 |
| Faul, C; Jaschonek, K; Renn, W; Schmidt, H | 1 |
| Maass, B; Müller, B; Skuballa, W; Stürzebecher, S | 1 |
| Skuballa, W; Vorbrüggen, H | 1 |
| Barbenel, JC; Belch, JJ; Forbes, CD; Lowe, GD; Prentice, CR; Saniabadi, AR | 1 |
| Asaka, N; Hayashi, Y; Kirimoto, T; Matsuura, N; Miyake, H; Nakano, M; Tajima, K | 1 |
| Koenig, HM; Pelligrino, DA; Santizo, RA; Xu, HL | 1 |
| Chirkov, YY; Holmes, AS; Horowitz, JD; Stewart, S; Willoughby, SR | 1 |
| Devaki, T; Ebenezar, KK; Sathish, V | 1 |
| Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M | 1 |
| Chien, S; Wheeler, TJ; Wiegand, CB | 1 |
| Chen, A; Chen, M; Chen, X; Dai, W; Dong, Q; Li, W; Li, X; Ou, C; Shen, Y | 1 |
1 trial(s) available for adenosine diphosphate and cardiovascular agents
| Article | Year |
|---|---|
Iloprost in peripheral vascular disease--platelet function and clinical outcome.
Topics: Adenosine Diphosphate; Blood Platelets; Cardiovascular Agents; Clinical Trials as Topic; Collagen; Epoprostenol; Humans; Iloprost; Male; Pain; Platelet Aggregation; Random Allocation; Vascular Diseases | 1987 |
14 other study(ies) available for adenosine diphosphate and cardiovascular agents
| Article | Year |
|---|---|
In vivo studies with the stabilized epoprostenol analogue taprostene. Effects on platelet functions and blood clotting.
Topics: Adenosine Diphosphate; Animals; Bleeding Time; Blood Coagulation; Blood Platelets; Cardiovascular Agents; Dose-Response Relationship, Drug; Epoprostenol; In Vitro Techniques; Injections, Intravenous; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Rabbits; Rats; Rats, Inbred Strains | 1990 |
Platelet responses observed during and after infusions of the prostacyclin analog ZK 36 374.
Topics: Adenosine Diphosphate; Arterial Occlusive Diseases; Blood Platelets; Cardiovascular Agents; Collagen; Epoprostenol; Fingers; Humans; Iloprost; Ischemia; Male; Middle Aged; Platelet Aggregation; Scleroderma, Systemic; Time Factors | 1985 |
Control of human and animal platelet aggregation by a new prostacyclin analog.
Topics: Adenosine Diphosphate; Animals; Cardiovascular Agents; Collagen; Dose-Response Relationship, Drug; Epinephrine; Epoprostenol; Humans; Iloprost; Male; Platelet Aggregation; Rabbits; Rats | 1985 |
Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Blood Platelets; Cardiovascular Agents; Colforsin; Cyclic AMP; Electrophoresis, Polyacrylamide Gel; Epoprostenol; Humans; Iloprost; In Vitro Techniques; Kinetics; Phosphorus Radioisotopes; Ribose | 1988 |
Antifibrillatory action of the stable orally active prostacyclin analogues iloprost and ZK 96 480 in rats after coronary artery ligation.
Topics: Adenosine Diphosphate; Animals; Arrhythmias, Cardiac; Blood Pressure; Cardiovascular Agents; Epoprostenol; Iloprost; Lidocaine; Platelet Aggregation; Rats; Rats, Inbred SHR; Reserpine | 1984 |
Synthesis of ciloprost (ZK 36 374): a chemically stable and biologically potent prostacyclin analog.
Topics: Adenosine Diphosphate; Cardiovascular Agents; Epoprostenol; Humans; Iloprost; Indicators and Reagents; Molecular Conformation; Platelet Aggregation; Prostaglandins; Structure-Activity Relationship | 1983 |
The novel effect of a new prostacyclin analogue ZK36374 on the aggregation of human platelets in whole blood.
Topics: Adenosine Diphosphate; Cardiovascular Agents; Collagen; Epoprostenol; Humans; Iloprost; Platelet Aggregation; Platelet Count; Thrombin | 1983 |
Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Body Weight; Cardiovascular Agents; gamma-Butyrobetaine Dioxygenase; Heart Failure; Heart Ventricles; Hemodynamics; Lactic Acid; Male; Methylhydrazines; Mixed Function Oxygenases; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Survival Rate | 2000 |
Chronic estrogen depletion alters adenosine diphosphate-induced pial arteriolar dilation in female rats.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Antifungal Agents; Arterioles; Calcium; Cardiovascular Agents; Endothelium, Vascular; Estrogens; Female; Glyburide; Hypoglycemic Agents; Indomethacin; Miconazole; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Nitroarginine; Ovariectomy; Peptides; Pia Mater; Potassium Channels; Rats; Rats, Sprague-Dawley; Theophylline; Vasodilation | 2001 |
Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiovascular Agents; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nitric Oxide; Nitroprusside; Perhexiline; Platelet Aggregation; Platelet Aggregation Inhibitors; Severity of Illness Index; Statistics as Topic; Stroke Volume; Ventricular Function, Left | 2002 |
Biochemical changes on the cardioprotective effect of nicorandil and amlodipine during experimental myocardial infarction in rats.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Amlodipine; Animals; Cardiovascular Agents; Drug Synergism; Isoproterenol; Lipid Metabolism; Male; Mitochondria, Heart; Myocardial Infarction; Nicorandil; Oxidation-Reduction; Rats; Rats, Wistar; Succinic Acid | 2003 |
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascular Agents; Clopidogrel; Collagen; Comorbidity; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Leukocyte Count; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardium; Necrosis; Peptides; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Prospective Studies; Ticlopidine; Tirofiban; Tyrosine; von Willebrand Factor | 2004 |
Fructose-1,6-bisphosphate enhances hypothermic preservation of cardiac myocytes.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Cardiovascular Agents; Cell Death; Dichloroacetic Acid; Fructosediphosphates; Glucose; Hypothermia, Induced; Insulin; Male; Myocytes, Cardiac; Preservation, Biological; Rats; Rats, Sprague-Dawley | 2005 |
Trimetazidine attenuates pressure overload-induced early cardiac energy dysfunction via regulation of neuropeptide Y system in a rat model of abdominal aortic constriction.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Aorta, Abdominal; Arterial Pressure; Cardiovascular Agents; Constriction; Disease Models, Animal; Energy Metabolism; Gene Expression Regulation; Hypertrophy, Left Ventricular; Male; Myocardium; Neuropeptide Y; Oxidative Stress; Rats, Wistar; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Receptors, Neuropeptide Y; Signal Transduction; Trimetazidine; Ventricular Function, Left; Ventricular Remodeling | 2016 |